516 completed, 126 terminated, 100 unknown, 66 recruiting. 395 Phase 2, 190 Phase 4, 154 Phase 3, 136 Phase 1, 73 Not applicable.
Follow Mycophenolic Acid: new trials by email Literature Review of Mycophenolic Acid trials Research Report on Mycophenolic Acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mycophenolate After Stem Cell Transplant for Systemic Sclerosis Mycophenolate Mofetil 1000 mg twice daily - Systemic Sclerosis (SSc) | Phase 2 | Not yet recruiting | Ottawa Hospital Research Institute | 6 | 2026-12-01 | 2026-10-19 |
| Safety and Efficacy of Secukinumab Versus Mycophenolate Mofetil in Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (SMART) Secukinumab, Mycophenolate mofetil (MMF) - Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | Phase 3 | Not yet recruiting | Chinese PLA General Hospital | 130 | 2026-11-15 | 2026-11-04 |
| Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers Cyclophosphamide, Busulfan, Fludarabine - Core Binding Factor Alpha Subunits, Hematologic Neoplasms | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 102 | 2026-11-11 | 2026-11-06 |
| CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus - Graft -Versus-host-disease | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 72 | 2026-11-01 | 2026-09-08 |
| Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 2 | Not yet recruiting | Stanford University | 30 | 2026-11-01 | 2026-09-30 |
| Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy Mycophenolate Mofetil (MMF), Prednisolon - IgA Nephropathy | Phase 2 | Not yet recruiting | Shaheed Suhrawardy Medical College and Hospital | 104 | 2026-09-01 | 2026-08-25 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy Mycophenolate Mofetil plus prednisone - Immune-mediated Hepatitis, Immune-related Adverse Event | Phase 2 | Recruiting | Fox Chase Cancer Center | 31 | 2026-07-23 | 2026-09-17 |
| PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab - Colitis, Hepatitis | Phase 2 | Not yet recruiting | Therakos LLC | 112 | 2026-07-01 | 2026-06-02 |
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2026-06-12 | 2026-07-01 |
| Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer Intensity-Modulated Radiation Therapy, Hypofractionated Radiation Therapy, Temozolomide (TMZ) - Advanced Glioblastoma | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 422 | 2026-06-10 | 2026-05-26 |
| Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Withdrawn | Mayo Clinic | 2026-06-01 | 2026-09-03 | |
| Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children rituximab, Mycophenolate Mofetil (MMF) Treatment, Cyclophosphamide - Lupus Nephritis | Not applicable | Not yet recruiting | Nanfang Hospital, Southern Medical University | 112 | 2026-06-01 | 2026-06-30 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone Kidney Biopsy, Voclosporin (LUPKYNIS), Blood, feces and urine sample collection - Lupus Nephritis, Systemic Lupus Erythematosus (SLE) | Phase 4 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 55 | 2026-04-23 | 2026-08-12 |
| PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA) - Lupus Nephritis | Phase 4 | Recruiting | Aurinia Pharmaceuticals Inc. | 150 | 2026-04-22 | 2026-08-03 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
Showing 20 of 912. Sign in to see all of them.
Leukemia, Myeloid, Acute (135) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (116) · Myelodysplastic Syndromes (115) · Leukemia, Lymphocytic, Chronic, B-Cell (102) · Lymphoma, Non-Hodgkin (98) · Hodgkin Disease (95) · Leukemia (86) · Multiple Myeloma (85) · Lymphoma (72) · Lymphoma, Follicular (67) · Lymphoma, Mantle-Cell (67) · Lymphoma, Large B-Cell, Diffuse (64) · Graft vs Host Disease (62) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (60) · Myeloproliferative Disorders (59)
Fred Hutchinson Cancer Center (79) · Novartis Pharmaceuticals (39) · Hoffmann-La Roche (34) · National Institute of Allergy and Infectious Diseases (NIAID) (34) · M.D. Anderson Cancer Center (24) · Masonic Cancer Center, University of Minnesota (24) · Astellas Pharma Inc (23) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (16) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (14) · Stanford University (13) · Novartis (12) · Bristol-Myers Squibb (10) · Memorial Sloan Kettering Cancer Center (10) · National Cancer Institute (NCI) (10) · City of Hope Medical Center (9)
United States (526) · Germany (81) · China (77) · Canada (68) · France (67) · Italy (60) · United Kingdom (47) · Spain (46) · South Korea (32) · Brazil (29) · Belgium (28) · Sweden (27) · Australia (26) · Netherlands (26) · Switzerland (22)
Brenda Sandmaier (18) · David Maloney (7) · Claudio G. Brunstein, MD, PhD (5) · Dolores Grosso, DNP, CRNP (5) · George Georges (5) · Neal Flomenberg, MD (5) · Usama Gergis, MD (5) · Christian P. Larsen, MD, DPhil (4)
PMID 32499241, PMID 39382091, PMID 39513526, PMID 34778952, PMID 38864363, PMID 21403127, PMID 22430088, PMID 18946341, PMID 18997171, PMID 19179301, PMID 26867033, PMID 28810721, PMID 30231851, PMID 30312541, PMID 32343796, PMID 33693991, PMID 35224732, PMID 35230699, PMID 36853224, PMID 40197799, PMID 42853965, PMID 10580071, PMID 11919310, PMID 12171484, PMID 12176626, PMID 12176628, PMID 12194926, PMID 12270445, PMID 12359731, PMID 12694055, PMID 12944064, PMID 14655180, PMID 14961990, PMID 15023160, PMID 15049798, PMID 15233820, PMID 15257455, PMID 15466923, PMID 15691277, PMID 15692967, PMID 15885236, PMID 15919463, PMID 16014059, PMID 16192477, PMID 16273116, PMID 16382014, PMID 16407509, PMID 16415388, PMID 16468960, PMID 16638802
P30CA015704 (50), P01CA018029 (15), P01CA078902 (12), 2009 (11), P01CA015396 (5), P01CA044991 (5), P30CA006973 (5), P30CA033572 (5), 2008 (4), 2014 (4), U01HL069294 (4), 2015 (3), 2025 (3), P30CA036727 (3), U24CA076518 (3)